UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM N-PX
ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED MANAGEMENT INVESTMENT COMPANY
Investment Company Act File number: 811-01528
Bruce Fund, Inc.
(Exact name of registrant as specified in charter)
_____________
20 North Wacker Drive, Suite 2414, Chicago, IL 60606
(Address of principal executive offices) (Zip code)
_____________
Robert B. Bruce
20 North Wacker Drive, Suite 2414
Chicago, Illinois 60606
(Name and address of agent for service)
Registrant's telephone number, including area code: 312-236-9160
Date of fiscal year end: June 30
Date of reporting period: 07/01/2020 - 06/30/2021
Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (Secs. 239.24 and 274.5 of this chapter),to file reports with the Commission, not later than August 31 of each
year, containing the registrant's proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b 1-4).The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.
A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget C'OMB") control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. Sec. 3507.
| Bruce Fund, Inc. | | | | | | | | |
| Annual Proxy Report | | | | | | | |
| Report Period: July 1, 2020 to June 30, 2021 | | | | | | |
| | | | | | | | | |
| Security | Ticker | Cusip | Meeting | Proposed | Description | Vote | For, Against | For or Against |
| Name | | | Date | (M) or (S) | | | or Abstain | Management |
| | | | | | | | | |
| Chevron | CVX | 166764100 | 5/26/2021 | M | Directors | Y | F | F |
| Chevron | CVX | 166764100 | 5/26/2021 | M | Auditors | Y | F | F |
| Chevron | CVX | 166764100 | 5/26/2021 | M | Executive Compensation | Y | F | F |
| Chevron | CVX | 166764100 | 5/26/2021 | S | Scope 3 emissions | Y | A | F |
| Chevron | CVX | 166764100 | 5/26/2021 | S | Net zero 2050 | Y | A | F |
| Chevron | CVX | 166764100 | 5/26/2021 | S | Public benefit | Y | A | F |
| Chevron | CVX | 166764100 | 5/26/2021 | S | Lobbying | Y | F | A |
| Chevron | CVX | 166764100 | 5/26/2021 | S | Independent Chairman | Y | A | F |
| Chevron | CVX | 166764100 | 5/26/2021 | S | Special meeting | Y | A | F |
| | | | | | | | | |
| Supernus | SUPN | 868459108 | 6/15/2021 | M | Directors | Y | F | F |
| Supernus | SUPN | 868459108 | 6/15/2021 | M | Auditors | Y | F | F |
| Supernus | SUPN | 868459108 | 6/15/2021 | M | Executive Compensation | Y | F | F |
| Supernus | SUPN | 868459108 | 6/15/2021 | M | Incentive Plan | Y | F | F |
| | | | | | | | | |
| Apple | APPL | 037833100 | 2/23/2021 | M | Directors | Y | F | F |
| Apple | APPL | 037833100 | 2/23/2021 | M | Accounting | Y | F | F |
| Apple | APPL | 037833100 | 2/23/2021 | M | Executive Compensation | Y | F | F |
| Apple | APPL | 037833100 | 2/23/2021 | S | proxy access | Y | A | F |
| Apple | APPL | 037833100 | 2/23/2021 | S | Executive Compensation improve | Y | A | F |
| | | | | | | | | |
| Newmont | NEM | 651639106 | 4/28/2021 | M | Directors | Y | F | F |
| Newmont | NEM | 651639106 | 4/28/2021 | M | Accounting | Y | F | F |
| Newmont | NEM | 651639106 | 4/28/2021 | M | Executive Compensation | Y | F | F |
| | | | | | | Y | | |
| Mannkind | MNKD | 56400P706 | 5/20/2021 | M | Directors | Y | F | F |
| Mannkind | MNKD | 56400P706 | 5/20/2021 | M | Accounting | Y | F | F |
| Mannkind | MNKD | 56400P706 | 5/20/2021 | M | Executive Compensation | Y | F | F |
| | | | | | | | | |
| Fate Theraputics | FATE | 31189P102 | 6/2/2021 | M | Directors | Y | F | F |
| Fate Theraputics | FATE | 31189P102 | 6/2/2021 | M | Accounting | Y | F | F |
| Fate Theraputics | FATE | 31189P102 | 6/2/2021 | M | Executive Compensation | Y | F | F |
| Fate Theraputics | FATE | 31189P102 | 6/2/2021 | M | New shares | Y | F | F |
| | | | | | | | | |
| Paratek | PRTK | 699374302 | 6/10/2021 | M | Directors | Y | F | F |
| Paratek | PRTK | 699374302 | 6/10/2021 | M | Accounting | Y | F | F |
| Paratek | PRTK | 699374302 | 6/10/2021 | M | Executive Compensation | Y | F | F |
| | | | | | | | | |
| Ashland Global | ASH | 044186104 | 1/28/2021 | M | Directors | Y | F | F |
| Ashland Global | ASH | 044186104 | 1/28/2021 | M | Accounting | Y | F | F |
| Ashland Global | ASH | 044186104 | 1/28/2021 | M | Executive Compensation | Y | F | F |
| Ashland Global | ASH | 044186104 | 1/28/2021 | M | Incentive plan | Y | F | F |
| | | | | | | | | |
| Merck | MRK | 58933Y105 | 5/25/2021 | M | Directors | Y | F | F |
| Merck | MRK | 58933Y105 | 5/25/2021 | M | Compensation | Y | F | F |
| Merck | MRK | 58933Y105 | 5/25/2021 | M | Accounting | Y | F | F |
| Merck | MRK | 58933Y105 | 5/25/2021 | S | Written consent | Y | A | F |
| Merck | MRK | 58933Y105 | 5/25/2021 | S | Covid-19 access | Y | A | F |
| | | | | | | | | |
| Chiasma | CHMA | 16706W102 | 6/10/2021 | M | Directors | Y | A | A |
| Chiasma | CHMA | 16706W102 | 6/10/2021 | M | Accounting | Y | F | F |
| Chiasma | CHMA | 16706W102 | 6/10/2021 | M | Executive Compensation | Y | F | F |
| Chiasma | CHMA | 16706W102 | 6/10/2021 | M | Compensation Vote Frequency | Y | 1Yr | F |
| | | | | | | | | |
| Pfizer | PFE | 717081103 | 4/22/2021 | M | Directors | Y | F | F |
| Pfizer | PFE | 717081103 | 4/22/2021 | M | Accounting | Y | F | F |
| Pfizer | PFE | 717081103 | 4/22/2021 | M | Executive Compensation | Y | F | F |
| Pfizer | PFE | 717081103 | 4/22/2021 | S | Covid-19 access | Y | A | F |
| Pfizer | PFE | 717081103 | 4/22/2021 | S | Political spending | Y | F | A |
| Pfizer | PFE | 717081103 | 4/22/2021 | S | Independent Chair | Y | A | F |
| | | | | | | | | |
| Nextera | NEE | 65339F101 | 5/20/2021 | M | Directors | Y | F | F |
| Nextera | NEE | 65339F101 | 5/20/2021 | M | Auditors | Y | F | F |
| Nextera | NEE | 65339F101 | 5/20/2021 | M | Compensation | Y | F | F |
| Nextera | NEE | 65339F101 | 5/20/2021 | M | Long term incentives | Y | F | F |
| Nextera | NEE | 65339F101 | 5/20/2021 | S | Written Consent | Y | A | F |
| | | | | | | | | |
| Allstate | ALL | 020002101 | 5/25/2021 | M | Directors | Y | F | F |
| Allstate | ALL | 020002101 | 5/25/2021 | M | Auditors | Y | F | F |
| Allstate | ALL | 020002101 | 5/25/2021 | M | Compensation | Y | F | F |
| Allstate | ALL | 020002101 | 5/25/2021 | S | Proxy access | Y | A | F |
| | | | | | | | | |
| Paratek Pharm. | PRTK | 699374302 | 6/9/2021 | M | Directors | Y | F | F |
| Paratek Pharm. | PRTK | 699374302 | 6/9/2021 | M | Auditors | Y | F | F |
| Paratek Pharm. | PRTK | 699374302 | 6/9/2021 | M | New shares | Y | F | F |
| | | | | | | | | |
| Bausch Health | BHC | 071734107 | 4/27/2021 | M | Directors | Y | F | F |
| Bausch Health | BHC | 071734107 | 4/27/2021 | M | Compensation | Y | F | F |
| Bausch Health | BHC | 071734107 | 4/27/2021 | M | Auditors | Y | F | F |
| | | | | | | | | |
| Flotek | FTK | 343389102 | 6/3/2021 | M | Directors | Y | F | F |
| Flotek | FTK | 343389102 | 6/3/2021 | M | Long term Incentive Plan | Y | F | F |
| Flotek | FTK | 343389102 | 6/3/2021 | M | Compensation | Y | F | F |
| | | | | | | | | |
| Amerco | UHAL | 023586100 | 8/20/2020 | M | Directors | Y | F | F |
| Amerco | UHAL | 023586100 | 8/20/2020 | M | Compensation | Y | F | F |
| Amerco | UHAL | 023586100 | 8/20/2020 | M | Compensation Vote Frequency | Y | 3 yrs. | F |
| Amerco | UHAL | 023586100 | 8/20/2020 | M | Accounting | Y | F | F |
| Amerco | UHAL | 023586100 | 8/20/2020 | S | Board Actions | Y | F | F |
| | | | | | | | | |
| Abbvie | ABBV | 00287Y109 | 5/7/2021 | M | Directors | Y | F | F |
| Abbvie | ABBV | 00287Y109 | 5/7/2021 | M | Auditors | Y | F | F |
| Abbvie | ABBV | 00287Y109 | 5/7/2021 | M | Say on Pay | Y | F | F |
| Abbvie | ABBV | 00287Y109 | 5/7/2021 | M | Incentive Stock | Y | F | F |
| Abbvie | ABBV | 00287Y109 | 5/7/2021 | M | Stock Purchase | Y | F | F |
| Abbvie | ABBV | 00287Y109 | 5/7/2021 | M | Supermajority elimination | Y | F | F |
| Abbvie | ABBV | 00287Y109 | 5/7/2021 | S | Lobbying | Y | F | A |
| Abbvie | ABBV | 00287Y109 | 5/7/2021 | S | Independent Chair | Y | A | F |
| | | | | | | | | |
| Prothena | PRTA | G72800108 | 5/18/2021 | M | Directors | Y | F | F |
| Prothena | PRTA | G72800108 | 5/18/2021 | M | Auditors | Y | F | F |
| Prothena | PRTA | G72800108 | 5/18/2021 | M | Compensation | Y | F | F |
| Prothena | PRTA | G72800108 | 5/18/2021 | M | Long term Incentive Plan | Y | F | F |
| Prothena | PRTA | G72800108 | 5/18/2021 | M | Distributable reserves | Y | F | F |
| | | | | | | | | |
| Abbott | ABT | 002824100 | 4/23/2021 | M | Directors | Y | F | F |
| Abbott | ABT | 002824100 | 4/23/2021 | M | Say on Pay | Y | F | F |
| Abbott | ABT | 002824100 | 4/23/2021 | M | Accounting | Y | F | F |
| Abbott | ABT | 002824100 | 4/23/2021 | S | Lobbying Disclosure | Y | F | A |
| Abbott | ABT | 002824100 | 4/23/2021 | M | Supermajority elimination | Y | F | F |
| Abbott | ABT | 002824100 | 4/23/2021 | S | Racial Justice | Y | A | F |
| Abbott | ABT | 002824100 | 4/23/2021 | S | Independent Chair | Y | A | F |
| | | | | | | | | |
| Sirius XM Holding | SIRI | 82968B103 | 6/3/2021 | M | Directors | Y | F | F |
| Sirius XM Holding | SIRI | 82968B103 | 6/3/2021 | M | Accounting | Y | F | F |
| | | | | | | | | |
| Duke Energy | DUK | 26441C204 | 5/6/2021 | M | Directors | Y | F | F |
| Duke Energy | DUK | 26441C204 | 5/6/2021 | M | Auditors | Y | F | F |
| Duke Energy | DUK | 26441C204 | 5/6/2021 | M | Compensation | Y | F | F |
| Duke Energy | DUK | 26441C204 | 5/6/2021 | S | Political contributions | Y | F | A |
| Duke Energy | DUK | 26441C204 | 5/6/2021 | S | Independent Chair | Y | A | F |
| Duke Energy | DUK | 26441C204 | 5/6/2021 | M | Supermajority elimination | Y | F | F |
| | | | | | | | | |
| Avista | AVA | 05379B107 | 5/11/2021 | M | Directors | Y | F | F |
| Avista | AVA | 05379B107 | 5/11/2021 | M | Auditors | Y | F | F |
| Avista | AVA | 05379B107 | 5/11/2021 | M | Compensation | Y | F | F |
| | | | | | | | | |
| Xtant Medical | XTNT | 98420P308 | 10/27/2020 | M | Directors | Y | F | F |
| Xtant Medical | XTNT | 98420P308 | 10/27/2020 | M | Auditors | Y | F | F |
| Xtant Medical | XTNT | 98420P308 | 10/27/2020 | M | Equity Incentive | Y | F | F |
| Xtant Medical | XTNT | 98420P308 | 10/27/2020 | M | Compensation | Y | F | F |
| | | | | | | | | |
| XCEL Energy | XEL | 98389B100 | 5/19/2021 | M | Directors | Y | F | F |
| XCEL Energy | XEL | 98389B100 | 5/19/2021 | M | Auditors | Y | F | F |
| XCEL Energy | XEL | 98389B100 | 5/19/2021 | M | Compensation | Y | F | F |
| XCEL Energy | XEL | 98389B100 | 5/19/2021 | S | Climate | Y | A | F |
| | | | | | | | | |
| IGM Biosciences | IGMS | 449585108 | 6/24/2021 | M | Directors | Y | F | F |
| IGM Biosciences | IGMS | 449585108 | 6/24/2021 | M | Auditors | Y | F | F |
| IGM Biosciences | IGMS | 449585108 | 6/24/2021 | M | Authorized shares | Y | F | F |
| | | | | | | | | |
| General Electric | GE | 369604103 | 5/4/2021 | M | Directors | Y | F | F |
| General Electric | GE | 369604103 | 5/4/2021 | M | Auditors | Y | F | F |
| General Electric | GE | 369604103 | 5/4/2021 | M | Compensation | Y | F | F |
| General Electric | GE | 369604103 | 5/4/2021 | M | Reverse Split | Y | F | F |
| General Electric | GE | 369604103 | 5/4/2021 | S | Board candidates | Y | A | F |
| General Electric | GE | 369604103 | 5/4/2021 | S | Independent Chair | Y | A | F |
| General Electric | GE | 369604103 | 5/4/2021 | S | Net Zero | Y | F | F |
| | | | | | | | | |
| CMS Energy | CMS | 125896100 | 5/7/2021 | M | Directors | Y | F | F |
| CMS Energy | CMS | 125896100 | 5/7/2021 | M | Auditors | Y | F | F |
| CMS Energy | CMS | 125896100 | 5/7/2021 | M | Compensation | Y | F | F |
| CMS Energy | CMS | 125896100 | 5/7/2021 | S | Greenwashing Audit | Y | A | F |
SIGNATURES
Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Bruce Fund, Inc.
By: /s/ Robert B. Bruce
Robert B. Bruce, President
Date: 8/12/2021
